AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02506556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYl719
Description: Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.~Dose reductions (two levels) are allowed. Each cycle is 28 days
Study NCT01097590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TLA Gut™ column
Description: Five consecutive treatment sessions. The therapy will be administrated every second day.
Study NCT01097590 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
Study NCT03163758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real Repetitive Transcranial Magnetic Stimulation
Description: The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
Study NCT03163758 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham Repetitive Transcranial Magnetic Stimulation
Description: The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
Study NCT04278287 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 59.92Gy and 2.14Gy in 28 fractions to PGTV and 50.4Gy and 1.8Gy in 28 fractions 5 days every week in 5.5 weeks.
Study NCT04278287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: 100mg/d weekly,repeatedly on the first day,by intravenous infusion in 5-6 weeks.
Study NCT03640390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: This group will receive Dexmedetomidine infusion at a rate of 0.5 mcg/kg/hour.
Study NCT03640390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: This group will receive Magnesium sulphate infusion at a rate of 15 mg/Kg/hour
Study NCT04278287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 weekly,by intravenous infusion in 5-6 weeks.
Study NCT02477696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive oral acalabrutinib as stated in arm description.
Study NCT02477696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Participants will receive oral ibrutinib as stated in arm description.
Study NCT02101853 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT
Study NCT02101853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asparaginase
Description: Given IM or IV
Study NCT02101853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT and IV or SC
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV or SC
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given IV or PO
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV or PO
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IT, IV, and PO
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, and PO
Study NCT03640390 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: This group will receive normal saline infusion
Study NCT00763425 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold polypectomy
Description: The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
Study NCT00763425 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional polypectomy
Description: The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
Study NCT03683225 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CTC-413
Description: pramipexole ER, given with aprepitant
Study NCT00212342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethisterone,Ethinylestradiol
Study NCT00212342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Study NCT04159857 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fetal head extraction technique during the cesarean section
Description: see above for the description about one-hand and two-hand fetal head extraction technique
Study NCT04159857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fetal head extraction technique during the cesarean section
Description: see above for the description about one-hand and two-hand fetal head extraction technique
Study NCT03117660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: vitamin A daily X3-4 weeks
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02101853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02101853 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy
Study NCT02101853 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo cranial radiation therapy
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Hydrocortisone
Description: Given IT
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02101853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT01217164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: no intervention
Description: received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
Study NCT02868489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LactoWise®
Description: blend of bacillus coagulans and galactomannans
Study NCT02868489 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium citrate)
Study NCT04510623 — intervention group
Intervention type: OTHER
Intervention: ARBs and/or ACE inhibitors
Description: This is an observational study only.
Study NCT04510623 — intervention group
Intervention type: OTHER
Intervention: Usual Care
Description: This is an observational study only.
Study NCT01451528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Umbilical Cord Blood
Description: Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
Study NCT02236871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 servings
Description: Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.
Study NCT02236871 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 4 servings
Description: Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
Study NCT01126814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib (Gleevec)
Study NCT04074369 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CRISPR-based Test
Description: CRISPR-based Test performed on sputum or BALF in TB suspects.
Study NCT03738670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous RFA
Description: Single session percutaneous extra-spinal bone metastasis destruction to achieve pain relief
Study NCT03373084 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
Study NCT03373084 — intervention group
Intervention type: OTHER
Intervention: ultrasound
Description: Magnetic Resonance Imaging (MRI) or ultrasound will be performed to determinate location of the lesion
Study NCT03373084 — intervention group
Intervention type: OTHER
Intervention: Self-questionnaire
Description: Self-questionnaire will be completed by patient. In this questionnaire patients will describe the circumstances of the injury and their personal characteristics and level of sporting practice.
Study NCT02405611 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: primary eduction
Description: The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
Study NCT02792413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Patients will receive a subcutaneous injection of Denosumab every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
Study NCT02792413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl (placebo)
Description: Patients will receive a subcutaneous injection of NaCl every 6 months for the duration of the study. In addition, they will receive vitamin D and calcium (which is the normal treatment) for the duration of the study.
Study NCT02608216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FLT
Description: \[18F\]FLT PET/CT scan, imaging tracer
Study NCT02608216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: \[18F\]FLT PET/CT scan
Study NCT02608216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribociclib
Description: therapeutic
Study NCT02608216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: therapeutic
Study NCT00566020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BW430C (lamotrigine)
Description: lamotrigine 50mg/day-400mg/day
Study NCT02282813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTAP101 Capsules
Description: At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
Study NCT02282813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol
Description: At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
Study NCT02282813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxercalciferol
Description: At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
Study NCT02282813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
Study NCT04940793 — intervention group
Intervention type: DEVICE
Intervention: POD FT
Description: Cataract surgery
Study NCT01544387 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bed Rest
Description: * Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position~* Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed~* Subjects may have limited bathroom privileges
Study NCT01544387 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Activity
Description: * Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed~* Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired.
Study NCT01827267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Study NCT01827267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Study NCT03644394 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Implantation of IMES sensors
Description: Surgical implantation of IMES sensors during routine surgery to improve prosthetic control
Study NCT04165278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperthermic baths
Description: Taking hyperthermic baths
Study NCT03792100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven emulsion for infusion
Description: Total Parenteral Nutrition
Study NCT03792100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hospital compounded All in one emulsion
Description: Total Parenteral Nutrition
Study NCT01463189 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: painACTION: Arthritis
Description: Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute booster sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs.
Study NCT03133442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somnomat V4
Description: Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
Study NCT01380028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral corticosteroids
Description: Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
Study NCT01380028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT05585463 — intervention group
Intervention type: PROCEDURE
Intervention: acupuncture
Description: Acupuncture with needles and intracutaneous needles in the ear or body. The insertion is done with gloves, a guide to puncture the needle, and exhaustive skin disinfection.
Study NCT02549742 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
Study NCT02549742 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator
Description: Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
Study NCT02549742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Administered intravenously or injected into the tumour before electroporation.
Study NCT01398579 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastroscopy
Description: 20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.~Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE.
Study NCT02171936 — intervention group
Intervention type: OTHER
Intervention: Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).
Study NCT00670475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piroxicam
Description: In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
Study NCT00670475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes.
Study NCT02519283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GUIDED-HF
Description: Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator directed team (TNC Team).~1. Disease education: Health literacy screen will identify barriers to understanding discharge and medication instructions.~2. Lifestyle interventions: Includes receiving smoking cessation information and instructions to track daily weights.~3. Guideline recommendations for medications and device referral: Includes determining the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.~4. Outpatient follow-up appointment: TNC Team will provide a scheduled appointment within 7 days and will conduct a home visit within 48 hours of ED discharge.
Study NCT02519283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Those in the standard care arm will receive structured ED discharge assessment to include:~1. discharge instructions;~2. medication reconciliation~3. encourage follow-up.
Study NCT03369886 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Optical Coherence Tomography Angiography (OCTA)
Description: The images will be obtained using a commercial swept-source OCT (SS-OCT) device (DRI OCT Atlantis; Topcon, Tokyo, Japan). SS-OCT uses infrared light, wavelength of 1050 nm which is longer than conventional SD-OCT, at 100,000 A-scans per second. This longer infrared light source has advantages of deep signal penetration through the retina and choroid. Its axial and transversal resolution is 7 and 20 μm in tissue, respectively. Volumetric OCT scans were taken from 6 × 6 mm cubes. Each cube consists of 320 clusters of 4 repeated B-scans centered on the fovea. Moving objects (mostly blood flows) are detected by measuring intensity fluctuations from these repeatedly scanned OCT images. Automated segmentation was performed by OCT software to separate each layer of the retina. The en-face images of the superficial capillary network were derived from an en-face slab, ranged from the internal limiting membrane (ILM) to the inner border of the inner nuclear layer (INL).